Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Volunteers Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of DCR-AUD in Healthy Volunteers

NCT05021640
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
DCR-AUD, Placebo for DCR-AUD
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
View directory record Official record
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RGLS8429 in Healthy Volunteers

NCT05429073
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RGLS8429, Placebo volume-matching RGLS8429 dose
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

NCT02215941
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 10:47 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT07231679
View directory record Official record
Conditions
Healthy Volunteers, Chronic Kidney Disease
Interventions
IGT-303, Placebo
Drug
Lead sponsor
Ingenia Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

NCT05134727
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessing Repeat Fit Testing for CRC

NCT03248661
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Now I'm Telling You
Behavioral
Lead sponsor
Richard Crosby
Other
Eligibility
30 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 30, 2026, 10:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diffusion MRI in Cervical Spondylotic Myelopathy (CSM)

NCT03296592
View directory record Official record
Conditions
Cervical Spondylotic Myelopathy
Interventions
MRI with DBSI technology
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

NCT00875628
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-00868554 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2009 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

NCT00606112
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2009 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Temperature Response to a Head-Neck Cooling System

NCT00025987
View directory record Official record
Conditions
Healthy
Interventions
Head and Neck Cooling System, Thermometer Pill
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01355016
View directory record Official record
Conditions
Drug Safety, Respiratory Syncytial Virus Infections
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Subanesthetic Concentrations of Nitrous Oxide - 1

NCT00000249
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
20% N2O, 30% N2O, 40% N2O
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 37 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 30, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluate the Effects of Citicoline on Mood in Healthy Adults

NCT07089238
View directory record Official record
Conditions
Healthy
Interventions
Citicoline, Placebo
Dietary Supplement
Lead sponsor
Kirin Holdings Company, Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

NCT01823406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT03432884
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

NCT05631704
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Midazolam, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

NCT01758432
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Apixaban, Placebo/Apixaban, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 30, 2026, 10:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Brain Activities in Cervical Dystonia

NCT02959645
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 78 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of NTRX-07 in Healthy Volunteers

NCT04375436
View directory record Official record
Conditions
Pain, Neuropathic
Interventions
NTRX-07-SDD
Drug
Lead sponsor
NeuroTherapia, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 30, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SeeMe: Using Automated Facial Tracking to Detect Voluntary Behavior in Brain Injury

NCT07560631
View directory record Official record
Conditions
Traumatic Brain Injury (TBI) Patients, Severe Traumatic Brain Injury
Interventions
SeeMe Multimodal Auditory Command Protocol
Diagnostic Test
Lead sponsor
Stony Brook University
Other
Eligibility
22 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

NCT05983939
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 30, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

NCT02148744
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions
XmAb7195, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 30, 2026, 10:47 PM EDT